Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47

DGAP-News: MorphoSys AG


/ Key word: Agreement/Miscellaneous





Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® in Combination with TTI-622, a Fusion... | June 13, 2022

Related Keywords

Germany ,New York ,United States ,United Kingdom ,Planegg ,Bayern ,Massachusetts ,Boston ,Delaware ,Canada ,America ,American ,Lance Leopold ,Catalina Loveman ,Chris Boshoff ,Christine Chiou ,Jenifer Antonacci ,Development Officer ,Xencor Inc ,Linkedin ,Twitter ,Nasdaq ,American Society Of Hematology ,Pfizer ,Pfizer Inc ,Public Affairs ,Group Vice ,Drug Administration ,Pfizer Global Product Development ,Exchange Commission ,Youtube ,Morphosys Us Inc ,European Medicines Agency ,Clinical Development Hematology ,Incyte Enter ,Clinical Trial Collaboration ,Fusion Protein Directed Against ,Chief Development Officer ,Pfizer Global Product ,Malte Peters ,Morphosys Chief Research ,Group Vice President ,American Society ,Annual Meeting ,North America ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Pfizer Oncology ,Breakthroughs That Change Patient ,Pfizer News ,Annual Report ,Looking Information ,Factors That May Affect Future ,Morphosy Annual Report ,Morphosys Ag Stock Exchange ,News ,Information ,Press Release ,Morphosys ,Key ,End ,Incyte ,Winter ,Into ,Linical ,Trial ,Collaboration ,Or ,N ,Combination ,Ith Mor De0006632003 ,